AstraZeneca's antibody treatment against COVID-19 is one step closer to full approval after the Therapeutic Goods Administration granted the cocktail provisional determination.
The drug - called EVUSHIELD - is a long-acting antibody cocktail for adults who do not have enough immunity from vaccinations alone.
The treatment has been shown to reduce severe illness by up to 67 per cent in mild to moderate COVID infections.
It's likely the drug will be available for immunocompromised and vulnerable Australians who are fully vaccinated as well as those who cannot receive a vaccine for valid medical reasons.
The TGA's determination means AstraZeneca is now able to submit an application to register the drug for use in Australia.
6281164562001australiacoronavirus
0 Comments